Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39
Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.
Read original at benzingaStocks · News reference
Full Transcript: Mesoblast FY 2026 Earnings Call
Mesoblast (NASDAQ:MESO) released full-year financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 26, 2026, 11:25 PM
- Checked
- Aug 26, 2026, 11:25 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Mesoblast shares are trading higher after the company reported better-than-expected FY sales results.
Read original at benzingaMesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate
Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.01 by 500 percent. This is a 50 percent increase over losses of $(0.09) per share from the same
Read original at benzingaMesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast Limited reported strong financial results for FY2026 with total revenue of US$120.3 million, driven by successful RYONCIL commercial launch generating US$115.2 million in net revenue. The company completed patient treatment in its Phase 3 trial for chronic low back pain (rexlemestrocel-L), with results expected mid-2027. Net losses were reduced 44% to US$57.5 million. The company is expanding RYONCIL into adult markets and developing next-generation CAR-MSC and oncolytic virus technologies.
Read original at globenewswire-inc